Japan’s Ministry of Health, Labour and Welfare has approved Myriad Genetics’ BRACAnalysis Diagnostic System to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
